You can buy or sell CBMG and other stocks, options, ETFs, and crypto commission-free!
Cellular Biomedicine Group, Inc. Common Stock, also called Cellular Biomedicine Group, is a clinical stage biopharmaceutical company, which engages in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. Read More Its technology includes immune system therapy for treatment of cancer indications and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases. The company was founded in 2009 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Seeking AlphaMay 4
Cellular Biomedicine Group, Inc. (CBMG) CEO Tony Liu on Q1 2019 Results - Earnings Call Transcript
Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Q1 2019 Earnings Conference Call May 1, 2019 8:30 AM ET Company Participants Tony Liu - Executive Director, CEO, CFO Derrick Li - Head of Strategy & IR Conference Call Participants Madhu Kumar - Robert W. Baird George Zavoico - B. Riley FBR Operator Greetings and welcome to Cellular Biomedicine First Quarter 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal prese...
Markets InsiderApr 30
Cellular Biomedicine Group Reports First Quarter 2019 Results and Highlights Operational Progress
NEW YORK and SHANGHAI, April 30, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported its financial results and business highlights for the first quarter ended March 31, 2019. "Early in 2019, we achieved the first of many milestones anticipated for this year in support of our immuno-oncology platform, as we initia...
Expected Aug 6, After Hours